Last month, we highlighted Isracann which has been focused on the Israeli cannabis market and is focused on becoming a premier, low-cost cannabis producer. The company has significant leverage to this attractive cannabis market and has secured three farms with cultivation licenses totaling 580,000 sq. ft.
Isracann has been working on further strengthening its balance sheet through a private placement and is well capitalized, having fully funded the buildout of 230,000 sq. ft. of cultivation facilities that can produce approx. 23,500 kilograms of premium cannabis on an annual basis. One of the important aspects of this opportunity pertains to this facility and how it gets licensed. The company’s facility is designed to be a IMC-GAP/GSP certified facility that will be constructed to meet all regulatory standards.
In late 2019, Isracann expects to complete its first harvest and plans to ramp up from there. The facility offers the company significant room to expand and we are favorable on this. We expect to see increasing demand for Israeli cannabis products and the focus on increasing production capacity is important for the company’s growth potential.
One of the reasons why we are excited about the Isracann opportunity is due to the climate in Israel as being ideal for cultivating cannabis. When you look at the economics associated with cultivating cannabis in Canada, you will see that it costs approx. $1.50 to $2.00 (on average) to produce each gram of cannabis. In Israel, the economics are much more attractive, and producers are able to grow cannabis for approx. $0.40 per gram. The leverage to the Israeli cannabis market is significant and we think economics will play a key role once the company starts cultivating cannabis. We see Israel as a potential major exporter to the European Union where cannabis legalization is being fast tracked and we are also seeing a rapidly maturing medical market.
Announces Plans to Raise Capital
Earlier this month, Isracann announced plans to raise capital through a non-brokered private placement. The company will be raising capital concurrently with its initial public offering (IPO) and will be offering units for $0.17 each. Each unit will be comprised of one common share and a full purchase warrant (can be exercised at $0.34 for a period of 24-months after the closing of the financing. Upon closing of the financing, Isracann will execute a 3-1 reverse split.
The company plans to use this capital for growth purposes, and we are monitoring how the team continues to execute from here. If you would like to be connected with the company to learn more, please contact email@example.com.
Pursuant to an agreement between StoneBridge Partners LLC and Atlas Blockchain Group (AKE) on behalf of Isracann Biosciences we have been hired for a period of 180 days beginning December 9, 2018 and ending July 9, 2019 to publicly disseminate information about (AKE) including on the Website and other media including Facebook and Twitter. We are being paid $10,000 per month (AKE) for or were paid “ZERO” shares of unrestricted or restricted common shares. We own zero shares of (AKE), which we purchased in the open market. We plan to sell the “ZERO” shares of (AKE) that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of (AKE) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.